Case: Patents/Injunctions (3d Cir.)

The Third Circuit affirmed the decision of the District of New Jersey denying Johnson & Johnson and Janssen Biotech Inc.'s motion for a preliminary injunction in this action alleging that Samsung Bioepis Co. Ltd. issued a license to a subsidiary of the Cigna Group in violation of Samsung’s contract with Janssen relating to the biologic generally referred to and marketed under the brand name “Stelara.” The appeals court agreed with the district court’s conclusion that Janssen failed to establish irreparable harm.